Solitary Oral Progression in a Well-controlled Sézary Syndrome
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0449Keywords:
Cutaneous T-Cell Lymphoma, Sézary syndrome, cutaneous T-cell lymphoma, mogamulizumab, pegylated liposomal doxorubicin, mouth diseases, mouth neoplasmsDownloads
References
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703– 1714. DOI: https://doi.org/10.1182/blood-2018-11-881268
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 2015; 33: 3766–3773. DOI: https://doi.org/10.1200/JCO.2015.61.7142
Rosebush MS, Allen CM, Accurso BT, Baiocchi RA, Cordell KG. Oral mycosis fungoides: a report of three cases and review of the literature. Head Neck Pathol 2019; 13: 492–499. DOI: https://doi.org/10.1007/s12105-018-0923-5
Rodrigues-Fernandes CI, Vargas PA, de Aquino IG, Lopes MA, Santos-Silva AR. Sézary syndrome: report of a rare case with perioral manifestation and review of the literature. Oral Oncol 2022; 134: 106134. DOI: https://doi.org/10.1016/j.oraloncology.2022.106134
Sultan AS, Mostoufi B, Papadimitriou JC, Koka R, Basile J, Younis RH. Large cell transformation of oral mycosis fungoides. Head Neck Pathol 2018; 12: 247–251. DOI: https://doi.org/10.1007/s12105-017-0840-z
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192–1204. DOI: https://doi.org/10.1016/S1470-2045(18)30379-6
Tzoumpa S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, El Aarbaoui T, Dereure O, et al. Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study). Br J Dermatol 2024; 191: 143–144. DOI: https://doi.org/10.1093/bjd/ljae153
Roelens M, de Masson A, Andrillon A, Ram-Wolff C, Biard L, Boisson M, et al. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome. Br J Dermatol 2022; 186: 1010–1025. DOI: https://doi.org/10.1111/bjd.21018
Published
How to Cite
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
